Spectrum and Incidence Trends of AIDS- and Non-AIDS-Defining Cancers between 2010 and 2015 in the French Dat'AIDS Cohort.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
09
07
2020
revised:
22
09
2020
accepted:
08
12
2020
pubmed:
15
12
2020
medline:
3
2
2022
entrez:
14
12
2020
Statut:
ppublish
Résumé
Cancer risk is higher in people living with HIV (PLWH) compared with the general population, and cancers related to age are expected to be most prevalent. We determined the spectrum and incidence rates of AIDS-defining cancers (ADC) and non-AIDS-defining cancers (NADC) and of lung, Hodgkin lymphoma (HL), head and neck (HNC), colon-rectum, anal, liver, breast, prostate, and urinary bladder cancers between January 2010 and December 2015 in the French Dat'AIDS cohort. Incidence rates were calculated by year and compared using the Among 44,642 patients, corresponding to 180,216.4 person-years (PY), 1,440 cancer cases occurred in 1,314 patients. ADC incidence was 191.4 (172.3-212.7)/10 Spectrum of NADCs has changed, with prostate and breast cancers becoming the most common despite their lower SIR. These results confirm the need to maintain regular epidemiologic cancer monitoring in order to update screening guidelines.
Sections du résumé
BACKGROUND
Cancer risk is higher in people living with HIV (PLWH) compared with the general population, and cancers related to age are expected to be most prevalent.
METHODS
We determined the spectrum and incidence rates of AIDS-defining cancers (ADC) and non-AIDS-defining cancers (NADC) and of lung, Hodgkin lymphoma (HL), head and neck (HNC), colon-rectum, anal, liver, breast, prostate, and urinary bladder cancers between January 2010 and December 2015 in the French Dat'AIDS cohort. Incidence rates were calculated by year and compared using the
RESULTS
Among 44,642 patients, corresponding to 180,216.4 person-years (PY), 1,440 cancer cases occurred in 1,314 patients. ADC incidence was 191.4 (172.3-212.7)/10
CONCLUSIONS
Spectrum of NADCs has changed, with prostate and breast cancers becoming the most common despite their lower SIR.
IMPACT
These results confirm the need to maintain regular epidemiologic cancer monitoring in order to update screening guidelines.
Identifiants
pubmed: 33310788
pii: 1055-9965.EPI-20-1045
doi: 10.1158/1055-9965.EPI-20-1045
doi:
Types de publication
Historical Article
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
554-563Informations de copyright
©2020 American Association for Cancer Research.
Références
Hleyhel M, Belot A, Bouvier AM, Tattevin P, Pacanowski J, Genet P, et al. Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis. 2013;57:1638–47.
Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS. 2017;12:6–11.
Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009;23:2337–45.
Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer. 2010;103:416–22.
Robbins HA, Shiels MS, Pfeiffer RM, Engels EA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS. 2014;28:881–90.
Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D'Souza G, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015;163:507–18.
Park LS, Tate JP, Sigel K, Rimland D, Crothers K, Gibert C, et al. Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era: 1997–2012. AIDS. 2016;30:1795–806.
Hernández-Ramírez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017;4:e495–504.
Park LS, Tate JP, Sigel K, Brown ST, Crothers K, Gibert C, et al. Association of viral suppression with lower AIDS-defining and non-AIDS-defining cancer incidence in HIV-infected veterans: a prospective cohort study. Ann Intern Med. 2018;169:87–96.
Yanik EL, Katki HA, Engels EA. Cancer risk among the HIV-infected elderly in the United States. AIDS. 2016;30:1663–8.
Shiels MS, Islam JY, Rosenberg PS, Hall HI, Jacobson E, Engels EA. Projected cancer incidence rates and burden of incident cancer cases in HIV-infected adults in the United States Through 2030. Ann Intern Med. 2018;168:866–73.
Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74:784–95.
Baris D, Karagas MR, Verrill C, Johnson A, Andrew AS, Marsit CJ, et al. A case-control study of smoking and bladder cancer risk: emergent patterns over time. J Natl Cancer Inst. 2009;101:1553–61.
Shiota M, Yokomizo A, Takeuchi A, Inokuchi J, Tatsugami K, Ohga S, et al. Smoking effect on secondary bladder cancer after external beam radiotherapy for prostate cancer. Jpn J Clin Oncol. 2016;46:952–7.
Khanal A, Budhathoki N, Singh VP, Shah BK. Second primary malignancy in bladder carcinoma - a population-based study. Anticancer Res. 2017;37:2033–6.
Hessol NA, Whittemore H, Vittinghoff E, Hsu LC, Ma D, Scheer S, et al. Incidence of first and second primary cancers diagnosed among people with HIV, 1985–2013: a population-based, registry linkage study. Lancet HIV. 2018;5:e647–55.
Hleyhel M, Hleyhel M, Bouvier AM, Belot A, Tattevin P, Pacanowski J, et al. Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort. AIDS. 2014;28:2109–18.
Pugliese P, Cuzin L, Cabié A, Poizot-Martin I, Allavena C, Duvivier C, et al. A large French prospective cohort of HIV-infected patients: the nadis cohort. HIV Med. 2009;10:504–11.
Beachler DC, Abraham AG, Silverberg MJ, Jing Y, Fakhry C, Gill MJ, et al. Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. Oral Oncol. 2014;50:1169–76.
Binder F, Belot A, Delafosse P, Remontet L, Woronoff A, Bossard N. Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012. Sante Publique France. 2013;1:121.
Yanik EL, Achenbach CJ, Gopal S, Coghill AE, Cole SR, Eron JJ, et al. Changes in clinical context for Kaposi's sarcoma and non-Hodgkin lymphoma among people With HIV infection in the United States. J Clin Oncol. 2016;34:3276–83.
Royse KE, El Chaer F, Amirian ES, Hartman C, Krown SE, Uldrick TS, et al. Disparities in Kaposi sarcoma incidence and survival in the United States: 2000–2013. PLoS One. 2017;12:e0182750.
Grabar S, Hleyhel M, Belot A, Bouvier A-M, Tattevin P, Pacanowski J, et al. Invasive cervical cancer in HIV-infected women: risk and survival relative to those of the general population in France. results from the French hospital database on HIV (FHDH)-agence nationale de recherches sur le SIDA et les hépatites virales (ANRS) CO4 cohort study. HIV Med. 2019;20:222–9.
Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Althoff KN, et al. Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. Lancet HIV. 2019;6:e240–9.
Abraham AG, D'Souza G, Jing Y, Gange SJ, Sterling TR, Silverberg MJ, et al. Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr. 2013;62:405–13.
Massad LS, Hessol NA, Darragh TM, Minkoff H, Colie C, Wright RL, et al. Cervical cancer incidence after up to 20 years of observation among women with HIV. Int J Cancer. 2017;141:1561–5.
Adebamowo SN, Famooto A, Dareng EO, Olawande O, Olaniyan O, Offiong R, et al. Clearance of type-specific, low-risk, and high-risk cervical human papillomavirus infections in HIV-negative and HIV-positive women. J Glob Oncol. 2018;4:1–12.
Lions C, Cabras O, Cotte L, Huleux T, Gagneux-Brugnon A, Makinson A, et al. Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT'AIDS cohort. BMC Infect Dis. 2019;19:278.
Taborelli M, Virdone S, Camoni L, Regine V, Zucchetto A, Frova L, et al. The persistent problem of late HIV diagnosis in people with AIDS: a population-based study in Italy, 1999–2013. Public Health. 2017;142:39–45.
Tron L, Lert F, Spire B, Dray-Spira R. Agence nationale de recherche sur le sida et les hépatites virales (ANRS)-Vespa2 study group. levels and determinants of breast and cervical cancer screening uptake in HIV-infected women compared with the general population in France. HIV Med. 2017;18:181–95.
Le Cornet C, Schildknecht K, Rossello Chornet A, Fortner RT, González Maldonado S, Katzke VA, et al. Circulating immune cell composition and cancer risk: a prospective study using epigenetic cell count measures. Cancer Res. 2020;80:1885–92.
He Q-F, Xu Y, Li J, Huang Z-M, Li X-H, Wang X. CD8+ T-cell exhaustion in cancer: mechanisms and new area for cancer immunotherapy. Brief Funct Genomics. 2019;18:99–106.
Helleberg M, Kronborg G, Ullum H, Ryder LP, Obel N, Gerstoft J. Course and clinical significance of CD8+ T-cell counts in a large cohort of HIV-infected individuals. J Infect Dis. 2015;211:1726–34.
D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:1944–56.
Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100:407–20.
Muñoz JP, Carrillo-Beltrán D, Aedo-Aguilera V, Calaf GM, León O, Maldonado E, et al. Tobacco exposure enhances human papillomavirus 16 oncogene expression via EGFR/PI3K/Akt/c-Jun signaling pathway in cervical cancer cells. Front Microbiol. 2018;9:3022.
Carrillo-Beltrán D, Muñoz JP, Guerrero-Vásquez N, Blanco R, León O, de Souza Lino V, et al. Human papillomavirus 16 E7 promotes EGFR/PI3K/AKT1/NRF2 signaling pathway contributing to PIR/NF-κB activation in oral cancer cells. Cancers (Basel). 2020;12.
Madathil S, Rousseau M-C, Joseph L, Coutlée F, Schlecht NF, Franco E, et al. Latency of tobacco smoking for head and neck cancer among HPV-positive and HPV-negative individuals. Int J Cancer. 2020;147:56–64.
Chabeda A, Yanez RJR, Lamprecht R, Meyers AE, Rybicki EP, Hitzeroth II. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res. 2018;5:46–58.
Lanoy E, Rosenberg PS, Fily F, Lascaux A-S, Martinez V, Partisani M, et al. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood. 2011;118:44–9.
Colón-López V, Shiels MS, Machin M, Ortiz AP, Strickler H, Castle PE, et al. Anal cancer risk among people With HIV infection in the United States. J Clin Oncol. 2018;36:68–75.
Heard I, Poizot-Martin I, Potard V, Etienney I, Crenn-Hebert C, Moore C, et al. Prevalence of and risk factors for anal oncogenic human papillomavirus infection among HIV-infected women in France in the combination antiretroviral therapy era. J Infect Dis. 2016;213:1455–61.
Lanoy E, Spano J-P, Bonnet F, Guiguet M, Boué F, Cadranel J, et al. The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. Int J Cancer. 2011;129:467–75.
Coghill AE, Engels EA, Schymura MJ, Mahale P, Shiels MS. Risk of breast, prostate, and colorectal cancer diagnoses among HIV-infected individuals in the United States. J Natl Cancer Inst. 2018;110:959–66.
Morlat P. Agence nationale de recherches sur le sida (France), France, Conseil national du SIDA, France, Ministère des affaires sociales et de la santé. Prise en charge médicale des personnes vivants avec le VIH–Recommandations du groupe d'experts [Internet]. 2018.
Chatignoux É, Remontet L, Colonna M, Grosclaude P, Cariou M, Billot-Grasset A, et al. Estimations régionales et départementales d'incidence et de mortalité par cancers en France, 2007-2016. 2019.
Sigel K, Wisnivesky J, Crothers K, Gordon K, Brown ST, Rimland D, et al. Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study. Lancet HIV. 2017;4:e67–73.